Bayer and Chiesi to address respiratory medical needs in China
Bayer and Chiesi Farmaceutici S.p.A, the international research-focused healthcare Group (Chiesi Group), today announced that they have entered into a strategic partnership in China to address local unmet medical needs of respiratory diseases. The partnership aims to integrate commercial expertise and resources of both companies in China to improve access to treatment options for Chinese patients suffering from respiratory diseases.
Chronic respiratory diseases are among the major noncommunicable diseases in China. Two of the most common are asthma and chronic obstructive pulmonary disease (COPD), both of which lead to high unmet medical needs among the Chinese population.
“As a global leader with over 85 years of track record and expertise in treating respiratory diseases, Chiesi is fully committed to the care and improvement of patients’ quality of life,” said Davide Dalle Fusine, general manager of Chiesi Pharmaceutical (Shanghai) Co. Ltd. “Through this new partnership with Bayer, we would further expand the access to benefit more patients in China. We are excited to join forces with Bayer and to contribute more in the management of chronic respiratory diseases.”
“In support of the Healthy China strategy, Bayer is dedicated to fulfilling its commitment to advancing chronic disease management and providing comprehensive solutions by leveraging our expertise in healthcare complemented by external know-how through partnerships,” said Wei Jiang, executive vice president and president of Bayer Pharmaceuticals Region China & APAC and president of Bayer Group Greater China. “We are pleased that the partnership with Chiesi expands our efforts to a broader spectrum of respiratory diseases, which enables us to help more patients suffering from respiratory disease to benefit from Chiesi’s established treatments. Collaborating with outstanding partners like Chiesi is a cornerstone of Bayer's strategy to transform innovation into meaningful solutions for patients in China.”
